Grant, Loan, Tax Credit or Equity: Which Funding Instrument Fits Your Startup?
Every startup eventually faces the same question, usually at the worst possible moment — when runway is short, a decision is urgent, and every option on the table looks both attractive and risky. The question is not simply "where can we get money?" It is "what kind of money should we be pursuing, and what will it cost us in ways that don't show up on a term sheet?"
The four main funding instruments available to most early-stage companies — grants, loans, tax credits, and equity — are not interchangeable. Each one has a different structural logic, different eligibility conditions, different implications for control and ownership, and different alignment with specific stages of a company's development. Choosing the wrong instrument at the wrong stage does not just mean leaving money on the table. It can mean taking on obligations your business cannot service, diluting ownership before you have leverage, or spending months on a funding process that was never going to fit your profile.
This post is a practical framework for thinking through which instrument — or which combination — fits where you actually are right now.
The question is not simply "where can we get money?" It is "what kind of money should we be pursuing — and what will it cost us in ways that don't show up on a term sheet?"
Section 01
The Four Instruments — What Each One Actually Is
Before comparing them, it is worth being precise about what each instrument actually involves — because the popular understanding of all four tends to be simpler than the reality.
Instrument 01 · Non-dilutive · Non-repayable
Grants
Who provides it
Govt., foundations, agencies
Repayment
None
Equity given up
None
Typical range (Canada)
$10K – $3M+
A grant is money you do not have to repay and do not give up equity to receive. It sounds like free money — and in one sense it is — but the real cost of a grant is in time, compliance, and fit. Grants are awarded for specific purposes, tied to specific activities, and subject to reporting requirements that impose a real administrative burden. Most government grants are also milestone-based, meaning funds are released against deliverables rather than deposited upfront.
The eligibility bar for grants is genuinely high and highly specific. A company that does not fit the funder's mandate — on sector, stage, geography, type of activity, or partnership structure — will not succeed in a grant competition regardless of how strong the business is. Grant applications are also slow: federal programs in Canada often run on 4–8 month review cycles. Grants work best as a complement to other capital, not as a primary operating lifeline.
In Canada, the most relevant programs for startups include IRAP (NRC's Industrial Research Assistance Program), SDTC (Sustainable Development Technology Canada), NSERC Alliance grants for industry-academic collaboration, and various provincial innovation grants. For international collaboration specifically, NSERC's Alliance International streams and the NFRF open new pathways that most startup founders have not explored.
Strengths
- No dilution, no repayment
- Validates R&D credibility
- Stacks with other instruments
- Can unlock larger follow-on grants
Limitations
- Slow — months to decision
- Narrow eligibility criteria
- Restricted use of funds
- Reporting & compliance burden
Instrument 02 · Non-dilutive · Repayable
Loans & Repayable Contributions
Who provides it
Banks, BDC, EDC, govt. programs
Repayment
Yes — with interest
Equity given up
None (unless convertible)
Typical range (Canada)
$50K – $5M+
A loan provides capital now in exchange for repayment over time, typically with interest. The key variants relevant to startups are: traditional commercial loans (from banks or BDC), which typically require revenue history and often collateral; government repayable contributions (from programs like ISED's Strategic Innovation Fund or provincial equivalents), which offer concessional terms but still require repayment; and convertible notes, which are loans that convert to equity at a future financing event — a common early-stage instrument that bridges the gap between loan and equity.
The fundamental logic of debt is that it is the right instrument when the business has clear, foreseeable cash flows to service the obligation. For pre-revenue startups, taking on debt is often premature — the repayment schedule creates a fixed obligation against uncertain income. For revenue-generating startups with a capital need that is operational rather than exploratory, debt can be significantly cheaper than equity in the long run because it preserves ownership.
Strengths
- No ownership dilution
- Faster than grants or equity rounds
- Tax-deductible interest
- Predictable cost of capital
Limitations
- Requires repayment capacity
- Often needs collateral or revenue history
- Creates fixed cash flow obligation
- Hard to access pre-revenue
Instrument 03 · Non-dilutive · Claim-based
Tax Credits & Refundable Incentives
Who provides it
Federal & provincial tax authorities
Repayment
None
Equity given up
Typical range (Canada)
15%–35% of eligible spend
Tax credits are perhaps the most underused funding instrument among early-stage founders — partly because they are administered through the tax system rather than a funding agency, and partly because their value is only realized after eligible activities have been completed and the claim has been filed. But for companies with any meaningful R&D expenditure, they are one of the highest-return funding mechanisms available.
Canada's SR&ED (Scientific Research & Experimental Development) program is the most significant. It allows Canadian-controlled private corporations (CCPCs) to claim a refundable tax credit of up to 35% on eligible R&D expenditures — meaning even a startup with no taxable income receives a cash refund. Federal and provincial SR&ED credits can stack, with combined effective rates in some provinces reaching 50–65% of qualifying spend. The 2024 federal budget also introduced the Clean Technology Investment Tax Credit and Clean Electricity Investment Tax Credit, creating new incentive layers for companies in energy, materials, and climate tech.
The catch is eligibility: SR&ED requires that the expenditure represent genuine scientific or technological advancement under conditions of uncertainty. Routine product development does not qualify. Keeping rigorous contemporaneous records of experimental work — hypotheses, iterations, results — is essential to a defensible claim.
Strengths
- Cash refund even with no tax owed
- Stacks with grants (in most cases)
- No application process — file with taxes
- Retroactive to eligible spend already made
Limitations
- Realized 12–18 months after spend
- Strict eligibility definitions
- Record-keeping burden is real
- CRA audit risk on large claims
Instrument 04 · Dilutive · Growth-oriented
Equity — Angels, VCs & Strategic Investors
Who provides it
Angel investors, VCs, strategics
Repayment
None (return via exit)
Equity given up
Typically 10–30% per round
Typical range (Canada)
$250K – $50M+
Equity financing means selling a share of your company in exchange for capital. The investor receives ownership — and with it, typically, some rights over company decisions — and their return comes through a liquidity event: acquisition, IPO, or secondary sale. There is no repayment schedule, but there is a permanent structural consequence: your ownership percentage is reduced, and the investor's interests are now formally part of your governance.
Equity is the right instrument when the capital requirement is too large for grants or debt, when the risk profile of the business is too high for lenders, and when the investor brings more than money — networks, market access, domain expertise, and credibility that accelerates growth in ways that funded capital alone cannot. It is the wrong instrument when founders take it before they have the leverage to negotiate fair terms, or when the amount raised is actually within the range that non-dilutive instruments could cover.
A common pattern among well-advised startups is to use grants and tax credits aggressively during the pre-seed and seed stage to extend runway and de-risk the business before an equity raise — arriving at the fundraising table with proof points that improve valuation and reduce dilution. The order matters as much as the instrument.
Strengths
- No repayment obligation
- Scales with company ambition
- Investor brings strategic value
- Right for high-risk, high-growth models
Limitations
- Permanent ownership dilution
- Governance rights for investors
- Exit pressure from day one
- Wrong fit for slow-growth or lifestyle businesses
Section 02
The Decision Matrix: Instrument Fit by Stage and Situation
The right instrument is rarely determined by a single variable. It emerges from the intersection of several: your stage of development, the nature of the activity being funded, your current ownership structure, your timeline, and your capacity to service obligations. The table below maps common startup situations to the instrument most likely to fit — and flags the ones most likely to misfire.
| Startup Situation | Best-fit instrument(s) | Why | Avoid |
|---|---|---|---|
| Pre-revenue, R&D intensive | Grants + SR&ED | No revenue to service debt; too early for equity leverage; R&D spend qualifies for credits | Loans — no repayment capacity |
| Pre-revenue, software / SaaS | Grants + Angel equity | Limited SR&ED eligibility for pure software; early angels provide both capital and market access | Large VC rounds before product-market fit |
| Early revenue, product validated | Revenue-based loan + Tax credits | Cash flows can service modest debt; preserves equity for a better-valued raise later | Premature Series A before leverage |
| Growth stage, scaling operations | VC equity + Credit facility | Scale requires capital beyond non-dilutive capacity; credit facility for working capital avoids unnecessary dilution | Grants — too slow for growth pace |
| Deep tech / long R&D timelines | Federal grants + SR&ED + Patient equity | Multi-year R&D benefits from grant stacking; patient capital from mission-aligned VCs avoids premature exit pressure | Short-term loans with tight repayment windows |
| Cleantech / climate / sustainability | SDTC / NRC grants + ITC (Investment Tax Credits) | Strong federal mandate for clean sector; new ITCs introduced 2024 create significant incentive layer | Generic commercial debt — wrong sector risk profile |
| International expansion / partnerships | Alliance / NFRF grants + Strategic investor | International collaboration grants fund the partnership structure; strategic investors in target markets add access and credibility | Non-targeted loans — wrong instrument for partnership costs |
Section 03
Stacking: When the Answer Is More Than One Instrument
One of the most important — and least understood — aspects of startup funding strategy is that the instruments are not mutually exclusive. The most capital-efficient companies use them in combination, deliberately structured to maximize total funding while minimizing dilution and obligation.
The concept is called funding stacking, and it is standard practice among well-advised deep tech and cleantech startups in Canada. A company might simultaneously hold an IRAP contribution agreement, an active SR&ED claim, a BDC working capital facility, and an angel round. Each instrument funds a different activity, carries different conditions, and occupies a different position in the company's capital structure.
A realistic stacking sequence for a Canadian deep-tech startup
Pre-seed: IRAP funding ($50K–$500K) for R&D salaries + SR&ED claim on eligible expenditure → non-dilutive capital that extends runway by 12–18 months.
Seed: Provincial innovation grant + angel round ($250K–$1M) + convertible note → mixed non-dilutive and dilutive capital, with the grant and SR&ED de-risking the angel's investment and improving valuation anchor.
Series A: VC equity round ($3M–$10M) + BDC venture debt + ongoing SR&ED claims → growth capital for commercialization, with venture debt funding working capital without additional dilution.
There are important rules for stacking. Some grant programs reduce their contribution when another government program covers the same costs — the principle of "no double-dipping on the same dollar" applies across most federal programs. SR&ED credits, however, can generally be claimed on expenditures that were also partially covered by grants, subject to specific rules. Structuring the stack correctly requires understanding these interactions — ideally before signing any contribution agreement.
Common stacking mistakes to avoid
Claiming SR&ED on the same dollar that was fully covered by a government grant (the grant reduces eligible expenditure, not eliminates it — but the rules are specific). Accepting a provincial grant that restricts concurrent federal applications without reading the terms. Taking a convertible note with a valuation cap that is set before grant funding has been secured — the grant money you receive post-signing will not improve your cap position but will affect your dilution at conversion.
Section 04
Five Questions That Determine Which Instrument to Pursue First
When a startup is evaluating funding options, the conversation often starts in the wrong place — with the instrument ("should we raise a round or apply for grants?") rather than with the underlying conditions that determine fit. The following five questions reframe the decision correctly.
What is the money actually for?
Grants fund specific activities — R&D, talent development, market validation, partnership development. Equity funds the company's growth broadly. Loans fund capital expenditure or working capital with foreseeable return. Tax credits reimburse eligible R&D spend already made. The nature of what you need the money to do should determine the instrument, not the other way around. A company that needs capital to hire three engineers for a two-year R&D program should be looking at IRAP and SR&ED first. A company that needs capital to acquire customers should be looking at equity or revenue-based financing.
What is your repayment capacity right now?
Be honest about this — not optimistic. If your revenue is zero or unpredictable, taking on debt that must be serviced in 12 months is not a funding strategy, it is a delayed crisis. If you have recurring revenue with predictable growth, modest debt is rational and preserves equity you will want later. The question is not whether you can imagine paying it back — it is whether your current financial model, stress-tested for a 30% revenue miss, can still service the obligation.
How much ownership leverage do you currently have?
Equity is most expensive when you have the least leverage — before product-market fit, before revenue, before a credible pipeline. Every dollar of non-dilutive capital (grants, tax credits, concessional loans) that you secure before an equity raise improves your leverage at that raise: it extends runway, funds de-risking milestones, and gives you the option to raise on your terms rather than under pressure. If you have not exhausted non-dilutive options before approaching equity investors, you are almost certainly leaving value on the table.
What is your timeline tolerance?
Federal grants take 4–8 months from application to funding. SR&ED claims take 12–18 months to become cash. Equity rounds take 3–9 months from first conversation to close. Loans from BDC can close in 4–8 weeks. If your runway is 6 months, pursuing a 12-month grant process is not a funding strategy — it is wishful thinking. Matching the instrument's timeline to your actual cash position is one of the most basic and most frequently violated principles of startup funding.
Does your sector, activity, and company structure make you eligible?
Grant eligibility is not flexible. Canadian-controlled private corporation status matters for SR&ED. Industry sector matters for SDTC and NRC programs. The type of activity — whether it constitutes genuine R&D under the CRA's definition, or genuine innovation under a given program's mandate — determines whether your application is competitive or simply disqualified. Before investing significant time in any application, confirm that your company profile actually fits the program's eligibility criteria. This sounds obvious. It is violated constantly.
Section 05
A Word on Government Programs Specific to Canada
For Canadian startups, the grant and incentive landscape is genuinely among the most generous in the world — but it is also complex, siloed across federal and provincial programs, and frequently misunderstood. A few programs are worth knowing by name:
Key federal programs for Canadian startups
IRAP (Industrial Research Assistance Program): NRC's flagship program for early-stage companies. Offers non-repayable contributions for R&D projects and access to Industrial Technology Advisors (ITAs) who provide ongoing advisory support. One of the most accessible and well-regarded programs in the country.
SR&ED: Federal tax incentive for R&D. CCPCs receive a refundable 35% credit on the first $3M of eligible expenditure. Larger companies receive a non-refundable 15% credit. Refundable means cash back even with no taxable income — directly relevant to pre-revenue startups.
SDTC (Sustainable Development Technology Canada): For cleantech and sustainability-focused companies. Provides contributions of $1M–$20M for technology demonstration projects. Recently restructured after governance review — check current program status before applying.
BDC (Business Development Bank of Canada): Crown corporation offering startup loans, venture debt, and equity investment. BDC's venture arm is also a significant LP in Canadian VC funds, making it relevant at both the direct and ecosystem level.
EDC (Export Development Canada): Focused on companies with international activity. Offers financing, insurance, and bonding products relevant to startups pursuing export markets or international partnerships.
Provincial programs worth knowing
Every province has its own innovation ecosystem with distinct programs. Ontario's Ontario Together Fund and OCE (Ontario Centres of Excellence), BC's Innovate BC, Quebec's Investissement Québec, and Alberta's AVIN (Alberta Vehicle Innovation Network) all run programs that can stack with federal instruments. Provincial SR&ED top-up credits can add 10–20 percentage points to the federal base rate, making the combined incentive particularly valuable in Ontario and Quebec.
Section 06
The Most Expensive Mistake: Sequencing Errors
After fifteen years of watching startups navigate funding, the single most expensive pattern is not choosing the wrong instrument — it is choosing the right instrument at the wrong time. Sequencing errors take several recognizable forms.
Raising equity too early
Taking a seed round before the company has exhausted IRAP and other non-dilutive options means selling equity at the lowest valuation point in the company's history, for capital that grants could have provided without dilution. A $200,000 IRAP contribution at the pre-seed stage, followed by SR&ED on the underlying R&D spend, can add 12–18 months of runway and one or two meaningful milestones — dramatically improving the terms of the subsequent equity raise.
Taking debt before revenue is predictable
A loan with a 24-month repayment schedule against revenue projections that have not yet been validated is not conservative financing — it is a forced outcome. If the revenue does not materialize on schedule, the repayment obligation does not flex. The company either raises emergency equity (at a distressed valuation) or defaults. Debt is a tool for companies with cash flow visibility, not for companies trying to get to cash flow visibility.
Applying for grants reactively
Grant applications written under runway pressure are almost always weaker than applications written from a position of strategic clarity. The company's narrative is defensive rather than ambitious, the partnership structure is rushed, and the research question is retrofitted around eligible categories rather than genuinely emerging from the company's R&D direction. Grant strategy works best as a proactive, forward-looking function — planned 6–12 months ahead of capital need, not 6–12 weeks before the account hits zero.
The right sequence for most deep-tech startups
Non-dilutive first (grants + SR&ED) → milestone-validated → equity raise at improved leverage → debt for working capital as revenue scales → ongoing SR&ED and grant stacking throughout. This sequence is not universal — SaaS companies have different profiles, and platform businesses may reach equity markets faster — but it is the right default for R&D-intensive companies building in Canada.
Work with Rainpax Global
Not Sure Which Instrument Fits Your Startup Right Now?
Rainpax Global works with early and growth-stage companies to map their funding landscape, identify the right instrument stack for their current position, and build the applications and partnerships that activate it. From grant strategy and SR&ED positioning to equity readiness and international funding pathways — we work across the full capital toolkit.
Book a Consultation
contact@rainpaxglobal.com · (+1) 778 668 6927
www.rainpaxglobal.com
